European decentralised CAR T manufacturing consortium launched
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.
List view / Grid view
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
The CDMO’s new site will support its work in cell and gene therapy.
CBER head makes surprise comeback just weeks after his abrupt resignation.